Publikationen, an denen er mitarbeitet PABLO ROJO CONEJO (33)

2025

  1. Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?

    Epidemiology and Infection, Vol. 153

2024

  1. Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study

    The Lancet Child and Adolescent Health, Vol. 8, Núm. 5, pp. 325-338

  2. Transmitted Drug Resistance and HIV Diversity Among Adolescents Newly Diagnosed With HIV in Spain

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 1, pp. 40-48

2023

  1. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

2022

  1. Children living with HIV in Europe: do migrants have worse treatment outcomes?

    HIV Medicine, Vol. 23, Núm. 2, pp. 186-196

  2. Factors associated with late presentation for HIV care in adolescents in Spain

    HIV Medicine, Vol. 23, Núm. 11, pp. 1195-1201

2021

  1. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population

    Journal of Pediatrics, Vol. 232, pp. 287-289.e4

  2. Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthood

    Medicine, Vol. 100, Núm. 15, pp. e25403

  3. Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group

    AIDS, Vol. 35, Núm. 12, pp. 1973-1985

  4. The CARMA Study: Early Infant Antiretroviral Therapy - Timing Impacts on Total HIV-1 DNA Quantitation 12 Years Later

    Journal of the Pediatric Infectious Diseases Society, Vol. 10, Núm. 3, pp. 295-301

2020

  1. Longitudinal evolution of vertically HIV/HCV–co-infected vs HCV–mono-infected children

    Journal of Viral Hepatitis, Vol. 27, Núm. 1, pp. 61-67

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Impact of HIV on the health-related quality of life in youth with perinatally acquired HIV

    World Journal of Pediatrics, Vol. 15, Núm. 5, pp. 492-498

  2. Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children

    PLoS ONE, Vol. 14, Núm. 8

  3. Reduced Time to Suppression among Neonates with HIV Initiating Antiretroviral Therapy Within 7 Days after Birth

    Journal of Acquired Immune Deficiency Syndromes, Vol. 82, Núm. 5, pp. 483-490

  4. Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

    PLoS ONE, Vol. 14, Núm. 10

2018

  1. Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children

    Journal of Acquired Immune Deficiency Syndromes

  2. Sleep Profile and Self-Reported Neuropsychiatric Symptoms in Vertically HIV-Infected Adolescents on cART

    Journal of Pediatric Infectious Diseases, Vol. 13, Núm. 4, pp. 300-307

  3. Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis

    Pediatric Infectious Disease Journal, Vol. 37, Núm. 3, pp. e48-e57

2017

  1. Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial

    Journal of Pediatrics, Vol. 185, pp. 117-123.e6